Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer

Biologics: Targets and Therapy

Volumn 4, Issue , 2010, Pages 237-243

  Flanigan, Jaclyn ^a   Deshpande, Hari ^a   Gettinger, Scott N ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

Non small cell lung cancer; Vandetanib; Zactima; ZD6474

Indexed keywords

EPIDERMAL GROWTH FACTOR; VANDETANIB; VASCULOTROPIN RECEPTOR;

ANTIPROLIFERATIVE ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL EVALUATION; DOWN REGULATION; DRUG EFFICACY; DRUG SCREENING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR CROSS-TALK; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 79959990401     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/BTT.S7223     Document Type: Review

References (62)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006; 24: 2137-2150.
2. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours. J Thorac Oncol. 2007; 2: 706-714.
3. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced nonsmall- cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005; 366: 1527-1537.
4. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Eng J Med. 2006; 355: 2542-2550.
5. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an openlabel randomised phase III trial. Lancet. 2009; 373: 1525-1531.
6. Ciardiello F, Bianco R, Damiano V, et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res. 2000; 6: 3739-3747.
7. Guy SP, Ashton S, Hughes G, et al. Gefitinib (Iressa, ZD1839) enhances the activity of the novel vascular-targeting agent ZD6126 in human colorectal cancer and non-small cell lung cancer (NSCLC) xenograft models. Clin Cancer Res. 2003; 9: 6142s (abstract B13).
8. Tonra JR, Deevi DS, Corcoran E, et al. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin Cancer Res. 2006; 12: 2197-2207.
9. Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. Oncogene. 2000; 19: 5548-5557.
10. Gille H, Kowalski J, Li B, et al. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem. 2001; 276: 3222-3230.
11. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003; 9: 669-676.
12. Munoz-Chapuli R, Quesada AR, Angel Medina M. Angiogenesis and signal transduction in endothelial cells. Cell Mol Life Sci. 2004; 61: 2224-2243.
13. Jain RK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science. 2005; 307: 58-62.
14. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. Embo J. 2000; 19: 3159-3167.
15. Isobe T, Herbst RS, Onn A. Current management of advanced non-small cell lung cancer: targeted therapy. Semin Oncol. 2005; 32: 315-328.
16. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350: 2129-2139.
17. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304: 1497-1500.
18. Paz-Ares L, Sanchez JM, García-Velasco A, et al. A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). J Clin Oncol. 2006 ASCO Annual Meeting Proceedings Part I. 2006; 24: 7020.
19. Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361: 947-957.
20. Pham D, Kris MG, Riely GJ, et al. Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol. 2006; 24: 1700.
21. Ciardiello F, Caputo R, Damiano V, et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res. 2003; 9: 1546-1556.
22. De Luca A, Carotenuto A, Rachiglio A, et al. The role of the EGFR signaling in tumor microenvironment. J Cell Physiol. 2008; 214: 559-567.
23. Hirata A, Ogawa S, Kometani T, et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res. 2002; 62: 2554-2560.
24. Petit AM, Rak J, Hung MC, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol. 1997; 151: 1523-1530.
25. Bianco R, Garofalo S, Rosa R, et al. Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. Br J Cancer. 2008; 98: 923-930.
26. Viloria-Petit AM, Kerbel RS. Acquired resistance to EGFR inhibitors: Mechanisms and prevention strategies. Int J Radiat Oncol Biol Phys. 2004; 58: 914-926.
27. Herbst RS, O’Neill VJ, Fehrenbacher L, et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol. 2007; 25: 4743-4750.
28. Hainsworth RH. A phase III, multicenter, placebo-controlled, double-blind, randomized clinical trial to evaluate the efficacy of bevacizumab (Avastin) in combination with erlotinib (Tarceva) compared with erlotinib alone for treatment of advanced non-small cell lung cancer after failure of standard first-line chemotherapy (BETA). Thoracic Oncol. 2008; 3: S302.
29. Miller VA, O’Connor P, Soh C, Kabbinavar F. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Onco l. 2009; 27: 18s (abstract LBA8002).
30. Wedge SR, Ogilvie DJ, Dukes M et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 2002; 62: 4645-4655.
31. Arao T, Fukumoto H, Takeda M, et al. Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474. Cancer Res. 2004; 64: 9101-9104.
32. Taguchi F, Koh Y, Koizumi F, et al. Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib (“Iressa”)-sensitive and resistant xenograft models. Cancer Sci. 2004; 95: 984-989.
33. Ciardiello F, Bianco R, Caputo R, et al. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res. 2004; 10: 784-793.
34. Wu W, Onn A, Isobe T, et al. Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. Mol Cancer Ther. 2007; 6: 471-483.
35. Holden SN, Eckhardt SG, Basser R, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol. 2005; 16: 1391-1397.
36. Tamura T, Minami H, Yamada Y, et al. A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol. 2006; 1: 1002-1009.
37. De Boer R, Humblet Y, Wolf J, et al. An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer. Ann Oncol. 2009; 20: 486-491.
38. Kiura K, Nakagawa K, Shinkai T, et al. A randomized, double-blind, phase IIa dose-finding study of vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. J Thorac Oncol. 2008; 3: 386-393.
39. Natale RB, Bodkin D, Govindan R, et al. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: Results from a two-part, double-blind, randomized phase II study. J Clin Oncol. 2009; 27: 2523-2529.
40. Heymach JV, Johnson BE, Prager D, et al. Randomized placebo- controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol. 2007; 25: 4270-4277.
41. Heymach JV, Paz-Ares L, De Braud F, et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol. 2008; 26: 5407-5415.
42. Davies AM, Ho C, Lara PN, et al. Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer. Clin Lung Cancer. 2006; 7: 385-388.
43. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005; 23: 5892-5899.
44. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol. 2007; 25: 1545-1552.
45. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol. 2004; 22: 785-794.
46. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol. 2004; 22: 777-784.
47. Hanrahan EO, Ryan AJ, Mann H, et al. Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin Cancer Res. 2009; 15: 3600-3609.
48. Hanrahan EO, Lin HY, Kim ES, et al. Distinct patterns of change in plasma cytokine and angiogenic factors and markers of benefit for vandetanib and/or chemotherapy in non-small cell lung cancer patients. J Clin Oncol. 2010; 28: 193-201.
49. Natale RB, Thongprasert S, Greco FA, et al. Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: a randomized, double-blind phase III trial (ZEST). J Clin Oncol. 2009; 27: abstract 8009.
50. De Boer R, Arrieta O, Gottfried M, et al. Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZEAL). J Clin Oncol. 2009; 27: 409s: abstract 8010.
51. Herbst RS, Sun Y, Korfee S, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advance non-small cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZODIAC). J Clin Oncol. 2009; 27: 807s: abstract CRA8003.
52. US National Institutes of Health. ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures. Aug 10, 2010. Available from: http://clinicaltrials. gov/ct2/show/NCT00404924. Accessed Aug 11, 2010.
53. US National Institutes of Health. Zactima in Non Small Cell Lung Cancer (NSCLC) ELderly Patients In Combination With or Versus Gemcitabine (ZELIG). Jul 13, 2010. Available from: http://clinicaltrials. gov/ct2/show/NCT00753714. Accessed Aug 11, 2010.
54. US National Institutes of Health. Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer. Dec 1, 2009. Available from: http://clinicaltrials.gov/ct2/show/NCT00687297. Accessed Mar 21, 2010.
55. US National Institutes of Health. Phase II of Zactima Maintenance for Locally Advanced or Metastatic NSCLC Following Platinum-doublet Chemotherapy. June 28, 2010. Available from: http://clinicaltrials.gov/ct2/show/NCT00777179. Accessed Aug 11, 2010.
56. US National Institutes of Health. Radiation Therapy (XRT)and ZD6474 in Non-Small Cell Lung Cancer (NSCLC). Apr 1, 2010. Available from: http://clinicaltrials.gov/ct2/show/NCT00745732. Accessed Aug 11, 2010.
57. US National Institutes of Health. Investigate the Maximum Tolerated Dose of Vandetanib and Concurrent Whole Brain Radiotherapy (WBRT) in Patients With Non-small Cell Lung Cancer (NSCLC) and Brain Metastases. Jan 25, 2010. Available from: http://clinicaltrials.gov/ct2/show/NCT00807170. Accessed Mar 21, 2010.
58. US National Institutes of Health. BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC. Feb 26, 2010. Available from: http://clinicaltrials.gov/ct2/show/NCT00410189. Accessed Mar 21, 2010.
59. US National Institutes of Health. Malignant Pleural Effusion With ZD6474. Jan 6, 2010. Available from: http://clinicaltrials.gov/ct2/show/NCT00402896. Accessed Mar 21, 2010.
60. US National Institutes of Health. Paclitaxel, Carboplatin, and High-Dose Radiation Therapy With or Without Vandetanib in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer. Oct 7, 2009. Available from: http://clinicaltrials.gov/ct2/show/NCT00975260. Accessed Mar 21, 2010.
61. US National Institutes of Health. Vandetanib, Carboplatin, and Paclitaxel in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed by Surgery. Feb 6, 2009. Available from: http://clinicaltrials.gov/ct2/show/NCT00459121. Accessed Mar 21, 2010.
62. US National Institutes of Health. Phase I Combination With Vinorelbine or Gemcitabine Plus Cisplatin in Locally Advanced or Metastatic NSCLC. Apr 8, 2009. Available from: http://clinicaltrials.gov/ct2/show/NCT00496275. Accessed Mar 21, 2010.